Introdução: O câncer do colo do útero (CCU) está entre os cinco tipos de cânceres mais frequentes em mulheres. Inicialmente, o tratamento indicado é a cirurgia. Já, quando a paciente apresenta fatores de risco associados à recidiva local, é feita a radioterapia pélvica adjuvante. Investigar o impacto do tratamento na Qualidade de Vida (QV) das mulheres com CCU pode auxiliar o planejamento de ações no sentido de reduzir ou evitar danos. Objetivo: Compilar as repercussões e os fatores que influenciam a QV de mulheres com CCU submetidas ao tratamento radioterápico. Método: Foi realizada uma revisão integrativa da literatura nas bases de dados MEDLINE (PubMed), LILACS e SciELO. Os critérios de inclusão foram artigos dos últimos cinco anos, de acesso aberto, escritos em português, inglês ou espanhol e que abordassem o tema definido total ou parcialmente. Resultados: Foram selecionados 17 artigos, entre os quais predominaram os estudos longitudinais prospectivos (n=9), seguidos dos estudos transversais (n=5) e estudos longitudinais retrospectivos (n=3). Ademais, houve a utilização de 15 diferentes questionários, sendo mais frequente o European Organization for Research And Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), que integrou oito estudos. Conclusão: A QV das mulheres submetidas à radioterapia foi influenciada por fatores socioeconômicos, educacionais, relações matrimoniais e modalidade da radioterapia. Apesar de os métodos de tratamento terem influenciado fatores individuais, como sintomas físicos e emocionais, não tiveram relação significativa com a QV geral. Estudos devem ser realizados para avaliar os efeitos da radioterapia em longo prazo.

e12617 Background: The combination of doxorubicin (DOX) with paclitaxel (PTX) is effective in the treatment of breast cancer (BC). However, DOX-associated cardiotoxicity (CTX) is aggravated by the use of PTX. There´s no consensus on which sequence is most safe. Methods: Prospective study of women with primary BC. All of participants received four cycles of DOX and 12 infusions of PTX. Participants were divided into two groups, at the discretion of the oncologist: Group 1-PTX before DOX and Group 2-DOX before PTX. CTX was defined as an absolute reduction in left ventricular ejection fraction (LVEF)>10% to a value <53%. Patients underwent clinical evaluation and echocardiography before treatment (phase 1) and one year after treatment (phase 2). Results: Sixty-nine women were evaluated: 19 in G1 and 50 in G2. The groups had similar clinical characteristics. The doses of radiation, DOX and PTX used were similar. Eight (11.6%) patients developed CTX: two (10.5%) in G1 and six (12.0%) in G2 (p=0.62). LVEF was similar between the groups in phase 1 (G1=65.1±3.5; G2=65.2±3.9; p=0.96), with a significant reduction after one year in both groups: G1=61.4±8.1% (p=0.021) and G2=60.8±7.6% (p<0.001). Although lower, LVEF remained similar between groups after phase 2 (p=0.79). Conclusions: In women with BC who underwent chemotherapy, the incidence of CTX at the end of the first year of treatment was similar regardless of whether DOX was used before or after PTX. [Table: see text]

Background: The combination of doxorubicin (DOX) with paclitaxel (PTX) effectively treats breast cancer (BC). However,DOX-associated cardiotoxicity (CTX) is aggravated by the use of PTX. Consensus is lacking about which drug sequence involves the most CTX. Objectives: To evaluate whether DOX followed by PXT or the reverse sequence has the greatest cardiotoxic potential in the treatment of BC. Methods: Prospective study of women with primary BC who received four cycles of DOX and 12 infusions of PTX. Participants were divided into Group 1 (G1; PXT before DOX) and Group 2 (G2; DOX before PXT) at the discretion of the oncologist. CTX was defined as an absolute reduction in left ventricular ejection fraction (LVEF) > 10% to a value <53%. Patients underwent clinical evaluations and echocardiography before treatment (Phase 1) and one year after treatment (Phase 2). Results: Sixty-nine women were evaluated: 19 in G1 and 50 in G2. The groups had similar clinical characteristics. The doses of radiation, DOX, and PTX used were similar. Eight (11.6%) patients developed CTX: two (10.5%) in G1 and six (12.0%) in G2 (p=0.62). The mean LVEF was similar between groups in Phase 1 (G1=65.1±3.5%; G2=65.2±3.9%; p=0.96), with a significant reduction noted after one year in both groups: G1=61.4±8.1% (p=0.021) and G2=60.8±7.6% (p<0.001). Although lower, mean LVEF remained similar between groups after Phase 2 (p=0.79). Conclusions: In women with BC who underwent chemotherapy, the incidence of CTX at the end of the first year of treatment was similar regardless of whether DOX was used before or after PTX.